Arix Bioscience Plc Capital Markets Meeting Today
September 18 2017 - 1:01AM
RNS Non-Regulatory
TIDMARIX
Arix Bioscience Plc
18 September 2017
Arix Bioscience hosts Capital Markets Meeting today
LONDON, 18 September, 2017: Arix Bioscience plc (LSE: ARIX)
("Arix Bioscience" or "Arix"), a global healthcare and life science
company supporting medical innovation, is today hosting its
inaugural Capital Markets Meeting for investors and analysts in
London.
Joe Anderson, Chief Executive Officer, and Jonathan Peacock,
Chairman, will provide an update on Arix Bioscience's strategy and
progress to date. The event will also include presentations from
additional members of the Arix Bioscience team as well as a number
of Arix Group Businesses, who will each provide a detailed overview
of their respective companies, objectives and potential.
The meeting will be held at Etc. Venues 8 Fenchurch Place,
Fenchurch Street, London EC3M 4PB, from 12:30 to 18:00 BST. The
event will start with an informal lunch buffet, followed by a
series of short presentations, question-and-answer sessions and
networking. No new material information will be disclosed.
Presenters at the Arix Capital Markets Meeting will include:
-- Joe Anderson, PhD, CEO of Arix Bioscience plc
-- Jonathan Peacock, Chairman of Arix Bioscience plc
-- Daniel O'Connell, MD, PhD, Arix Bioscience plc
-- Mark Chin, Arix Bioscience plc
-- Christian Itin, PhD, CEO and Chairman of Autolus
-- Niall Martin, PhD, CEO of Artios Pharma
-- Jerry McMahon, PhD, President and CEO of Harpoon Therapeutics
-- Corey Fishman, MSM, CEO of Iterum Therapeutics
-- Gordon Hamilton, MA MD MBBS MBA, CEO of Depixus
-- Mike Moran, MBE, CEO of Proton Partners International
A live webcast of the event, with presentation slides, will be
available on the Arix website at:
https://edge.media-server.com/m6/p/2ypqux2r. A replay will be
available on the website shortly after the event.
Ends
For more information, please contact:
Arix Bioscience plc
Joe Anderson, CEO
+44 (0)20 7290 1052
Matthew Cole, Communications Director
+44 (0)20 7290 1065
Consilium Strategic Communications
Mary-Jane Elliott, Jessica Hodgson, Ivar Milligan
+44 (0)20 3709 5700
arix@consilium-comms.com
About Arix Bioscience plc
Arix Bioscience plc is a global healthcare and life science
company supporting medical innovation. Headquartered in London and
with an office in New York, Arix Bioscience sources, finances and
builds world class healthcare and life science businesses
addressing medical innovation at all stages of development.
Operations are supported by privileged access to breakthrough
academic science and strategic relationships with leading research
accelerators and global pharmaceutical companies.
Arix Bioscience plc is listed on the Main Market of the London
Stock Exchange.
For further information, please visit www.arixbioscience.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAGGUQUBUPMPUM
(END) Dow Jones Newswires
September 18, 2017 02:01 ET (06:01 GMT)
Arix Bioscience (LSE:ARIX)
Historical Stock Chart
From Apr 2024 to May 2024
Arix Bioscience (LSE:ARIX)
Historical Stock Chart
From May 2023 to May 2024